France· FR:62679768
APIDRA 100 Unités/ml, solution injectable en cartouche
A medicinal product containing insuline glulisine, registered in France by SANOFI AVENTIS (ALLEMAGNE), on the national reimbursement list.
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- INSULINE GLULISINE
- Manufacturer
- SANOFI AVENTIS (ALLEMAGNE)
- Country
- France (FR)
- ATC code
- —
- Reimbursed
- Yes
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- cip1334009365694235 cartouche(s) en verre de 3 mlEUR 26.69
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Insuline glulisine in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaAPIDRASanofi-Aventis Deutschland GmbH, Frankfurt am Main
- United KingdomApidra 100units/ml solution for injection 10ml vialsSanofi
- SpainAPIDRA 100 UNIDADES/ml OPTICLIK SOLUCION INYECTABLE EN CARTUCHOSanofi-Aventis Deutschland Gmbh
- FinlandApidraSanofi-Aventis Deutschland GmbH
- SwitzerlandApidra
- IcelandApidraSanofi-Aventis Deutschland GmbH
- ItalyAPIDRA*1 flaconcino SC 10 ml 100 U/mlSANOFI AVENTIS DEUTSCHL.GMBH
- Japanインスリングルリジン（遺伝子組換え）サノフィ
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Apidra, Apidra Solostar
- Liechtenstein · Apidra, Apidra Solostar
- Norway · Apidra, Apidra Solostar
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/b1df9110-0239-4d15-b069-41aac4708d9e GET /v1/drugs/b1df9110-0239-4d15-b069-41aac4708d9e?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "62679768",
"date_amm": "2004-09-27",
"type_amm": "Procédure centralisée",
"numero_ue": "EU/1/04/285",
"substance": "INSULINE GLULISINE",
"statut_amm": "Autorisation active",
"statut_bdm": null,
"forme_pharmaceutique": "solution injectable",
"voies_administration": "sous-cutanée",
"etat_commercialisation": "Commercialisée",
"surveillance_renforcee": "Non"
}See everything about insuline glulisine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.